Avra, Inc. (OTCMKTS: AVRN) is a specialty pharmaceutical company focused on the research, development and manufacture of topical and transdermal drug products. The company’s core business activities include formulation development, clinical support and commercial-scale manufacturing for both proprietary and generic pharmaceutical and cosmeceutical products. Avra’s technology platforms are designed to enhance the delivery of active ingredients through the skin barrier, ensuring consistent dosage, improved patient compliance and reduced systemic side effects.
Avra’s product portfolio spans analgesics, anti‐inflammatory treatments, dermatological therapies and wound‐care formulations. In addition to its own branded offerings, the company provides contract development and manufacturing services (CDMO) to pharmaceutical and biotechnology clients. Its in‐house capabilities encompass pre‐formulation studies, stability testing, scale‐up optimization and regulatory‐compliant production, enabling partners to advance topical candidates through clinical trials to market launch.
Headquartered in the United States with a state‐of‐the‐art formulation laboratory, Avra also operates a manufacturing facility in Southeast Asia. Through these complementary sites, the company serves healthcare markets across North America, Europe, Asia-Pacific and select emerging regions. Avra’s global footprint allows it to navigate diverse regulatory landscapes, support international supply chains and respond to customer needs with both small‐batch clinical production and high‐volume commercial runs.
Founded in 2011, Avra has grown through strategic acquisitions and internal R&D investments. The company is led by a management team with decades of experience in pharmaceutical development, regulatory affairs and operations. Under the leadership of CEO Gary Hu—who brings over 20 years of expertise from major multinational drugmakers—Avra continues to expand its topical drug delivery platforms and bolster its contract services business. The board of directors comprises industry veterans in formulation science, quality assurance and global commercialization.
AI Generated. May Contain Errors.
Free AVRN Stock Alerts